# Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

> **NCT00185588** · PHASE1,PHASE2 · COMPLETED · sponsor: **George Albert Fisher** · enrollment: 33 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Vatalanib
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00185588
- **Lead sponsor:** George Albert Fisher
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2009-01
- **Final completion:** 2009-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185588, "Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00185588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*